Chronic refractory gout is a substantial burden for many1-3
Affecting approximately 160,000 people in the United States, chronic refractory gout is a painful and severe form of inflammatory arthritis that can lead to bone erosions and joint deformities resulting in loss of function and disability.1,2
92% of patients with chronic refractory gout develop an immunogenic response to treatment that is associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle.3
References: 1. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58(9):2587-2590. 2. Edwards NL, Sundy JS, Forsythe A, et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14:10-15. 3. Krystexxa® [package insert]. Lake Forest, IL: Horizon Pharma Rheumatology LLC; 2018. 4. Kishimoto TK, Maldonado RA. Nanoparticles for the induction of antigen-specific immunological tolerance. Front Immunol. 2018;9:230. 5. Sands E, Kivitz AJ, DeHaan W, et al. Update of SEL-212 phase 2 clinical data in symptomatic gout patients: SVP-rapamycin combined with pegadricase mitigates immunogenicity and enables sustained reduction of serum uric acid levels, low rate of gout flares and monthly dosing. Poster presentation at: 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting; October 19-24, 2018; Chicago, IL. Poster #2254.